CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2026 AND INDEPENDENT AUDITOR'S REVIEW REPORT

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2026
WITH INDEPENDENT AUDITOR'S REVIEW REPORT

TABLE OF CONTENTS	PAGES

الدكتور محمد العمري وشركاه
Dr. Mohamed Al-Amri & Co.

Head office: Moon Tower - 8 Floor
P.O. Box 8736, Riyadh 11492
Unified Number : 92 002 4254
Fax : +966 11 278 2883

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED FINANCIAL STATEMENTS

The Shareholders of
Canadian General Medical Center Complex Company
(A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying interim condensed statement of financial position of Canadian General Medical Center Complex Company - "Saudi Joint Stock Company" ("the Company") as of June 30, 2026, and the related interim condensed statement of profit or loss and other comprehensive income for the three-month and six-month periods then ended, and the interim condensed statements of changes in equity and cash flows for the six-month period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed financial statements in accordance with International Accounting Standard 34 –Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" that is endorsed in the Kingdom of Saudi Arabia. A review of interim condensed financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed financial statements are not prepared in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

For Dr. Mohamed Al-Amri & Co.

د. محمد العمري وشركاه - محاسبون قانونيون
شركة مهنية رقم ٣٢٣/١١/٦٦/٢
س.ت ٢٠٥٠١٠٥٨٢٢
Dammam
Certified Public Accountants
Dr. Mohamed Al-Amri & Co.

Ahmed Al Jumah
Certified Public Accountant
Registration No. 621

Dammam, on: 26 Safar, 1448 (H)
Corresponding to: 09 August, 2026 (G)

Dr. Mohammed Al-Amri & Co. Chartered Accountants, a professional closed joint stock company registered in the Kingdom of Saudi Arabia under CR no. 1010433982, with paid-up capital of SAR (1,000,000) is a member of BDO International Limited, a UK Company Limited by guarantee, and forms part of the international BDO network of independent member firms.
Jeddah: P.O. Box 784 Jeddah 21421 Dammam: P.O. Box 2590 Dammam 31461
info@bdoalamri.com | www.bdoalamri.com

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2026
(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

	Notes	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
ASSETS			
Non-current assets			
Property and equipment	4	**22,855,360**	23,447,277
Right-of-use assets	5	**4,803,005**	6,054,306
Total non-current assets		**27,658,365**	29,501,583
Current assets			
Inventories		**4,995,261**	2,847,893
Trade receivables	6	**65,216,671**	59,249,948
Prepayments and other receivables		**8,626,050**	7,088,564
Investments at fair value through profit or loss (FVTPL)	7	**24,554,057**	30,115,550
Cash and cash equivalents		**5,844,226**	4,200,466
Total current assets		**109,236,265**	103,502,421
TOTAL ASSETS		**136,894,630**	133,004,004
EQUITY AND LIABILITIES			
Equity			
Share capital		**77,000,000**	77,000,000
Actuarial reserve		**(2,451,141)**	(1,472,351)
Retained earnings		**20,898,681**	20,522,863
Treasury shares	13	**(666,920)**	-
Total equity		**94,780,620**	96,050,512
Liabilities			
Non-current liabilities			
Employees' benefits obligations		**9,748,934**	8,165,158
Lease liabilities	5	**2,520,809**	2,924,950
Total non-current liabilities		**12,269,743**	11,090,108
Current liabilities			
Trade and other payables		**18,824,160**	19,755,671
Short term loan	8	**4,575,455**	-
Due to related parties	10	**3,209,999**	964,764
Lease liabilities	5	**2,198,793**	3,090,258
Provision for zakat	9	**1,035,860**	2,052,691
Total current liabilities		**29,844,267**	25,863,384
Total liabilities		**42,114,010**	36,953,492
TOTAL EQUITY AND LIABILITIES		**136,894,630**	133,004,004

The accompanying notes from 1 to 20 form an integral part of these un-audited interim condensed financial statements.

Saad

Chief Financial Officer | **Chief Executive Officer** | **Chairman**

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2026
(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

		Three-Month Period Ended		**Six-Month Period Ended**	
		June 30, 2026	June 30, 2025	**June 30, 2026**	June 30, 2025
	Note	**(Un-audited)**	(Un-audited)	**(Un-audited)**	(Un-audited)
Revenue	11	**38,659,246**	32,253,331	**76,702,884**	62,342,504
Cost of revenue		**(28,476,374)**	(23,939,207)	**(58,347,446)**	(45,183,212)
Gross profit		**10,182,872**	8,314,124	**18,355,438**	17,159,292
General and administrative expenses		**(4,163,414)**	(3,964,947)	**(8,081,342)**	(6,573,046)
Selling and marketing expenses		**(809,550)**	(591,966)	**(1,575,406)**	(1,382,721)
Expected credit loss on trade receivables	6	**(636,563)**	(247,857)	**(45,490)**	(507,468)
Operating profit		**4,573,345**	3,509,354	**8,653,200**	8,696,057
Fair value changes of investments at FVTPL		**(248,942)**	(1,960,610)	**(561,493)**	983,453
Finance cost		**(295,791)**	(219,494)	**(534,963)**	(434,337)
Other income, net		**16,444**	-	**16,444**	87,709
Profit before Zakat		**4,045,056**	1,329,250	**7,573,188**	9,332,882
Zakat	9	**(548,113)**	(497,694)	**(1,037,370)**	(1,055,983)
Net profit for the period		**3,496,943**	831,556	**6,535,818**	8,276,899
Other comprehensive (loss) income					
Items that will not be reclassified to profit or loss in subsequent periods:					
(Loss) / gain on remeasurement of employees' benefit obligations		**(667,463)**	79,552	**(978,790)**	(491,317)
Total comprehensive income for the period		**2,829,480**	911,108	**5,557,028**	7,785,582
Basic and diluted earnings per share	15	**0.05**	0.01	**0.08**	0.11

The accompanying notes from 1 to 20 form an integral part of these un-audited interim condensed financial statements.

Chief Financial Officer	**Chief Executive Officer**	**Chairman**

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

	Share capital	Actuarial reserve	Retained earnings	Treasury shares	Total
For the six-month period ended June 30, 2025 (un-audited)					
Balance at January 01, 2025	77,000,000	(856,463)	17,725,975	-	93,869,512
Net profit for the period	-	-	8,276,899	-	8,276,899
Other comprehensive loss	-	(491,317)	-	-	(491,317)
Total comprehensive income for the period	-	(491,317)	8,276,899	-	7,785,582
Dividend (note 14)	-	-	(3,850,000)	-	(3,850,000)
Balance at June 30, 2025	**77,000,000**	**(1,347,780)**	**22,152,874**	**-**	**97,805,094**
For the six-month period ended June 30, 2026 (un-audited)					
Balance at January 01, 2026	**77,000,000**	**(1,472,351)**	**20,522,863**	**-**	**96,050,512**
Net profit for the period	**-**	**-**	**6,535,818**	**-**	**6,535,818**
Other comprehensive loss	**-**	**(978,790)**	**-**	**-**	**(978,790)**
Total comprehensive income for the period	**-**	**(978,790)**	**6,535,818**	**-**	**5,557,028**
Dividend (note 14)	**-**	**-**	**(6,160,000)**	**-**	**(6,160,000)**
Buy back of treasury shares (note 13)	**-**	**-**	**-**	**(666,920)**	**(666,920)**
Balance at June 30, 2026	**77,000,000**	**(2,451,141)**	**20,898,681**	**(666,920)**	**94,780,620**

The accompanying notes from 1 to 20 form an integral part of these un-audited interim condensed financial statements.

Saad

Chief Financial Officer **Chief Executive Officer** **Chairman**

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY
(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF CASH FLOWS
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

	For the six-month period ended	
	June 30,2026 (Un-audited)	June 30,2025 (Un-audited)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before zakat	**7,573,188**	9,332,882
Adjustments for non-cash items:		
Depreciation of property and equipment	**2,272,743**	1,655,585
Depreciation on right-of-use assets	**1,504,353**	1,294,038
Employees' benefits obligations – provision	**759,856**	740,698
Finance cost	**534,963**	434,337
Gain on disposal of property and equipment	**(15,335)**	(8,696)
Expected credit loss on trade receivables	**45,490**	507,468
Fair value changes of investments at FVTPL	**561,493**	(983,453)
	13,236,751	12,972,859
Changes in working capital		
Inventories	**(2,147,368)**	(904,167)
Trade receivables	**(6,012,213)**	(10,253,993)
Prepayments and other receivables	**(1,537,486)**	3,534,317
Trade and other payables	**(1,014,096)**	6,259,140
Due to related parties	**2,245,235**	1,358,760
Cash generated from operations	**4,770,823**	12,966,916
Employees' benefits obligations paid	**(374,265)**	(679,672)
Zakat paid	**(2,054,201)**	(2,152,074)
Net cash generated from operating activities	**2,342,357**	10,135,170
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments at FVTPL	**-**	(35,318,854)
Proceeds from sale of investments at FVTPL	**-**	35,331,196
Redemption of investments at FVTPL	**5,000,000**	-
Purchases of property and equipment	**(1,684,621)**	(6,466,291)
Proceeds from disposal of property and equipment	**19,130**	8,696
Net cash generated from / (used in) investing activities	**3,334,509**	(6,445,253)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net change in short-term loan	**4,575,455**	-
Dividend paid	**(6,160,000)**	(3,850,000)
Repayment of lease liabilities	**(1,781,641)**	(1,557,725)
Purchase of treasury shares	**(666,920)**	-
Net cash used in financing activities	**(4,033,106)**	(5,407,725)
Net change in cash and cash equivalents	**1,643,760**	(1,717,808)
Cash and cash equivalents at beginning of the period	**4,200,466**	4,659,967
Cash and cash equivalents at end of the period	**5,844,226**	2,942,159
Significant non-cash transactions:		
Additions to property and equipment transferred from inventory	**-**	1,011,330
Additions to right-of-use assets and lease liabilities (note 5)	**253,052**	660,192

The accompanying notes from 1 to 20 form an integral part of these un-audited interim condensed financial statements.

Saad

Chief Financial Officer	**Chief Executive Officer**	**Chairman**

1. ORGANIZATION AND ACTIVITIES

Canadian General Medical Center Complex Company (the "Company") is a Saudi joint stock company initially incorporated as a limited liability company registered in Dammam, Kingdom of Saudi Arabia under Commercial Registration No. 2050058605 dated Safar 13, 1429H (corresponding to February 20, 2008).

During the year 2020, the Company increased its share capital in several stages from ⃁ 2 million to ⃁ 77 million in addition to the entry of new shareholders. Later on, the shareholders of the Company decided to convert the Company from a Limited Liability Company to a Saudi Joint Stock Company under the same Commercial Registration. The Company obtained Ministerial approval for the said conversion on Jumada Al-Awwal 15, 1442 H, corresponding to December 30, 2020. The Capital Market Authority, in its decision issued on Dhu al-Qi'dah 18, 1442 -H (corresponding to June 28, 2021), approved the Company's request to register its shares for direct listing in the Parallel Market – Nomu.

In 2023, the Company's Board of Directors resolved in their meeting held on July 6, 2023, to approve the transition of the Company's listing from the Parallel Market (Nomu) to the Main Market, subject to obtaining the required regulatory approvals. On July 27, 2025, the Company submitted its application for the transition to the main market through the designated online portal provided by the relevant regulatory authorities. On October 1, 2025 (corresponding to 09/04/1447H), the Saudi Exchange issued its resolution approving the Company's request to transfer from the Nomu – Parallel Market to the Main Market. The Company is currently operating in the main market "TASI" of the Saudi Exchange.

The main activities of the Company are management of hospitals and health centers and trade in hospital tools and equipment and ambulances under License No. 3810301201210045 dated Jumada Al-Awwal 18, 1436 -H (corresponding to March 9, 2015).

The Company's registered office is located at Dammam, Kingdom of Saudi Arabia.

These interim condensed financial statements include the assets, liabilities and financial results of the Company and its following branches:

Branch CR No.	CR Date (Hijri)	CR Date (Gregorian)	City
2050116858	03/11/1439-H	16/07/2018-G	Dammam
2055026411	22/04/1439-H	09/01/2018-G	Jubail
2059004078	08/06/1438-H	07/03/2017-G	Abqaiq
2051056715	15/05/1435-H	16/03/2014-G	Khobar
1009042659	18/11/1445-H	26/05/2024-G	Riyadh

2. STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION

These interim condensed financial statements have been prepared in accordance with International Accounting Standard 34 - "Interim Financial Reporting" (IAS-34) as endorsed in the Kingdom of Saudi Arabia and other standards and pronouncement that are issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA").

These interim condensed financial statements do not include all the information and disclosures required in annual financial statements and therefore, should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2025. In addition, results for the six-month period ended June 30, 2026 are not necessarily indicative of the results that may be expected for the financial year ending December 31, 2026.

The significant judgements made by management in applying the Company's key sources of estimation uncertainty are similar to those described in the Company's annual financial statements for the year ended December 31, 2025.

These interim condensed financial statements have been presented in Saudi Riyals ("⃁") which is also the functional currency of the Company. All figures have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

3. MATERIAL ACCOUNTING POLICIES

The methods of computation and accounting policies adopted in the preparation of these interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2025, except for the following accounting policy and amendments which applied for the first time in 2026.

3.1 Treasury shares

Own equity instruments that are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in interim condensed statement of profit or loss and other comprehensive income on the purchase, sale, issue or cancellation of the Company's own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognised in retained earnings.

3.2 Standards and amendments issued and effective in current period

There are no new standards issued, however, there are amendments to the following standards, which are effective in current period and have no material impact on Company's interim condensed financial statement;

Amendments to standard	Description	Effective for annual years beginning on or after
IFRS 9 & IFRS 7	Amendments - Classification and Measurement of Financial Instruments	January 1, 2026

3.3 Impact of accounting standards issued but not yet effective

There are a number of standards and interpretations which have been issued by the International Accounting Standards Board that are effective for periods beginning subsequent to December 31, 2026 (the date of the Company's next annual financial statements) that the Company has decided not to adopt early. These are explained in the Company's annual financial statements for the year ended December 31, 2025.

<u>IFRS 18 'Presentation and Disclosure in Financial Statements'</u>

IFRS 18 'Presentation and Disclosure in Financial Statements' is effective for annual reporting periods beginning on or after January 1, 2027 and will replace IAS 1 'Presentation of Financial Statements'. The Company has not early adopted this accounting standard in preparing these interim condensed financial statements; however, earlier application is permitted. On adoption, the Company will apply IFRS 18 retrospectively.

IFRS 18 introduces new requirements for the presentation of the statement of profit or loss and other comprehensive income, disclosure requirements for management-defined performance measures and enhanced principles for the aggregation and disaggregation of information in the financial statements and notes. IFRS 18 does not change the recognition and measurement of items in the financial statements, accordingly net profit for the year, earnings per share and total equity will not be affected. The Company has performed an initial assessment of the expected impacts of IFRS 18 on its financial statements, the results of which are set out below. The assessment is ongoing and the expected impacts described below are preliminary and may change as the Company finalizes its implementation of IFRS 18.

3. MATERIAL ACCOUNTING POLICIES (CONTINUED)

3.3 Impact of accounting standards issued but not yet effective (Continued)

<u>IFRS 18 'Presentation and Disclosure in Financial Statements' (Continued)</u>

a. Structure of the Statement of Profit and Loss

The key changes include the requirements to classify all income and expense into one of these categories: operating, investing, financing, zakat and taxation and discontinued operations. Classification of income and expenses depends on the main business activities of the Company. The Company has determined that it does not have a main business activity of investing in assets and/or providing financing to customers.

Based on the information currently available, the Company expects the following changes to the current structure of the statement of profit or loss and other comprehensive income:

- Fair value gain/loss on investments held at FVTPL will be reclassified as part of the investing category.
- Dividend income from investments held at FVTPL will be classified and presented under the investing category.
- The Company will recognize another subtotal after the operating profit, named as "Profit or Loss before financing and zakat". This subtotal will include gain / loss from the investments, including the dividend income from investments and fair value gain or loss on investments held at FVTPL.
- The finance cost includes expenses from the employees' defined benefits obligations, short term loans and lease liabilities. These are currently presented within the sub-total of Profit before Zakat and after the operating profit. After the implementation of IFRS 18, both of these expenses will be classified under the subtotal of the financing category and a new subtotal will be created as 'Profit or Loss before zakat'.
- Bank charges and other charges not related to raising finance will be reclassified and presented under the operating category.
- In case of any other income or expense (except for Zakat and discontinued operations), such as recovery of written off trade debts and disposal gain / loss on property and equipment, the Company will recognize such incomes and expenses in the operating category and will be included in the operating profit or loss of the Company.

b. Principles of aggregation and disaggregation

IFRS 18 introduces enhanced requirements for the aggregation and disaggregation which focuses on grouping items based on their shared characteristics, including specific presentation or disclosure matters identified through management implementation assessment. It also introduces guidance on labelling and describing items presented in the primary financial statements or disclosed in the notes.

The management is currently assessing the characteristics of the assets, liabilities, equity items, income, expenses and cashflows when determining which information should be aggregated and what information should be disaggregated. Based on this, management will present line items in the primary financial statements that provide useful structured summaries and disclose additional material information in the notes. The management is also assessing line items currently labelled as "others" and will use more informative labels.

3. MATERIAL ACCOUNTING POLICIES (CONTINUED)

3.3 Impact of accounting standards issued but not yet effective (Continued)

IFRS 18 'Presentation and Disclosure in Financial Statements' (Continued)

c. Management defined Performance Measures

Management-defined performance measures (MPMs) are subtotals of income and expenses used in public communication outside the financial statements that reflect management's view of the Company's financial performance as a whole. The Company will be required to disclose specific information about MPMs in a single note in the financial statements including a reconciliation of each MPM to the most directly comparable subtotal specified by the IFRS Accounting Standards.

The Company is in process of determining which public communications should be considered when identifying MPMs. MPMs relate to the same reporting period as the financial statements, therefore, MPMs disclosed upon adoption of IFRS 18 will be determined based on public communications issued by the Company relating to 2027 interim reporting period.

d. Consequential amendments

IFRS 18 introduces consequential amendments to "IAS 7 – Statement of Cashflows", which require the Company to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows using the indirect method. The Company currently uses "profit/loss for the year before Zakat" as the starting point of the reconciliation of operating activities. Certain adjusting items included in the reconciliation will change as a result of this amendment.

The consequential amendments also provide specific guidance on the classification of interest and dividends. The Company will classify cash flows from interest paid as financing activities rather than operating activities, in line with the new guidance. Cash flows from interest and dividends received will be classified as investing activities and dividends paid will continue to be classified as financing activities. The assessment of consequential amendments to the statement of cashflows is ongoing and will be completed prior to the standard's effective date.

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

4. PROPERTY AND EQUIPMENT

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Net book value at beginning of period / year	**23,447,277**	16,920,881
Additions during the period / year	**1,684,621**	9,356,533
Transfer from inventories	**-**	1,011,330
Depreciation charged during the period / year	**(2,272,743)**	(3,790,607)
Net book value of disposals during the period / year	**(3,795)**	(50,860)
Net book value at the end of the period / year	**22,855,360**	23,447,277

5. RIGHT OF USE ASSETS AND LEASE LIABILITIES

The Company leases buildings and vehicles. The average term of the lease contracts ranges from 3 to 19 years.

Right of use assets

The following is a reconciliation of changes in right-of-use assets:

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Net book value at beginning of period / year	**6,054,306**	7,288,505
Additions during the period / year	**253,052**	1,531,536
Adjustments	**-**	(38,009)
Depreciation charged during the period / year	**(1,504,353)**	(2,727,726)
Net book value at the end of the period / year	**4,803,005**	6,054,306

Lease liabilities

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Balance at beginning of period / year	**6,015,208**	7,315,778
Additions during the period / year	**253,052**	1,531,536
Interest expense during the period / year	**232,983**	548,292
Adjustments	**-**	(40,694)
Paid during the period / year	**(1,781,641)**	(3,339,704)
Balance at the end of the period / year	**4,719,602**	6,015,208
Less: current portion	**(2,198,793)**	(3,090,258)
Non-current portion	**2,520,809**	2,924,950

6. TRADE RECEIVABLES

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Trade receivables	**73,800,941**	67,788,728
Less: Expected credit loss	**(8,584,270)**	(8,538,780)
Balance at the end of the period / year	**65,216,671**	59,249,948

Trade receivables include an amount of ⃁ 18.8 million (2025: ⃁ 16.7 million) from a single customer.

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

6. TRADE RECEIVABLES (CONTINUED)

Movement of expected credit loss:

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Opening balance	**8,538,780**	6,671,401
Charged during the period / year	**420,355**	1,867,379
Reversed during the period / year	**(374,865)**	-
Closing balance	**8,584,270**	8,538,780

7. INVESTMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS (FVTPL)

During the year 2024, the Company's management entered into a local Discretionary Portfolio Management ("DPM") agreement managed by the investment manager. The Company has elected to classify such investments at fair value through profit or loss (FVTPL). The value of said investments as at June 30, 2026 amounted to ⃁ 24,554,057 including cash amounted to ⃁ 1,126,461 (December 31, 2025: ⃁ 30,115,550 including cash amounted to of ⃁ 10,549,823). The fair value loss during the six-month period ended June 30, 2026 is amounting to ⃁ 561,493 (June 30, 2025: fair value gain of ⃁983,453)

8. SHORT TERM LOAN

During the six-month period ended June 30, 2026, the Company entered into Tawarruq facility agreement with a local commercial bank in the Kingdom of Saudi Arabia. The facility is available to support the Company's working capital requirements.

During the six-month period ended June 30, 2026, the Company made drawdowns amounting to ⃁ 4.5 million (June 30, 2025: Nil) under the facility. The drawdown balance is classified under current liabilities as it is payable within twelve months from the reporting period. The credit facility carries interest rates at SIBOR plus 4.5% per annum and is secured against a promissory note issued by the Company.

9. PROVISION FOR ZAKAT

A- Movement of zakat provision

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Balance at beginning of the period / year	**2,052,691**	2,158,827
Charged during the period / year	**1,037,370**	2,045,973
Payments during the period / year	**(2,054,201)**	(2,152,109)
Balance at the end of the period / year	**1,035,860**	2,052,691

B- Status of zakat assessment

The Company has submitted its Zakat returns till the year ended December 31, 2025, and obtained the zakat certificate. Further, the Company has received the initial assessment requirements from Zakat, Tax and Customs Authority "ZATCA" for the year 2025 and it is still in progress. The final assessment for the year 2025 has not yet been issued.

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

10. TRANSACTIONS AND BALANCES WITH RELATED PARTIES

10.A It includes entities under common directorship, Board of Directors (executive and non-executive members) and the key management personnel of the Company. The following are the benefits paid or due to key management personnel for their services:

	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)
Short-term employee benefits and salaries	**2,249,908**	1,574,154
End of service benefits	**106,105**	90,622
	2,356,013	1,664,776

10.B The transactions with related parties during the period are as follows:

Related party	Nature of transaction	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)
Khairat Al-Ammariah Real Estate Co. (Entity under common directorship)	Lease rentals of building	**588,898**	588,898
Mehan for Human Resources (Entity under common directorship)	Recruitment services	**6,111,806**	2,403,966

10.C Due to related parties

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Mehan for Human Resources	**2,532,766**	964,764
Khairat Al-Ammariah Real Estate Co.	**677,233**	-
	3,209,999	964,764

11. REVENUE

	For the three-month ended		For the six-month ended	
	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)
Corporate customers – Medical clinic project contracts	**38,050,120**	31,566,489	**75,589,586**	61,163,757
Individual customers – Medical clinics sector	**609,126**	686,842	**1,113,298**	1,178,747
	38,659,246	32,253,331	**76,702,884**	62,342,504

	For the three-month ended		For the six-month ended	
	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)
At point in time	**2,570,942**	5,705,365	**6,541,118**	7,953,455
Over time	**36,088,304**	26,547,966	**70,161,766**	54,389,049
	38,659,246	32,253,331	**76,702,884**	62,342,504

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

12. SEGMENT REPORTING

The Company has one segment, which is providing of medical services, The Company operates only in the Kingdom of Saudi Arabia and has no other geographical segment.

Transactions with major customers
The revenue from one of the major customers represent 35% of the total amount of the revenue for the period ended June 30, 2026 (June 30, 2025: 45%).

13. TREASURY SHARES

On June 15, 2025, the Extraordinary General Assembly approved the Company's purchase of a number of its own shares, with a maximum of 500,000 shares, for the purpose of allocating them to the Company's employees within the Employee Share Scheme. The purchase will be financed from the Company's own resources. The Board of Directors shall be authorized to complete the purchase within a maximum period of eighteen months from the date of the resolution of the Extraordinary General Assembly. The Company shall retain the purchased shares for a period not exceeding ten years from the date of the Extraordinary General Assembly's approval, as the maximum period for allocation to eligible employees. Upon the expiry of this period, the Company shall follow the procedures and regulations stipulated in the relevant laws and regulations.

During the six-month period ended June 30, 2026, the Company repurchased its own shares (124,977 number of shares) equivalent to ⃁ 666,920 from the open market. The repurchased shares are classified as treasury shares and are recognized as a deduction from equity as presented in the interim condensed statement of changes in equity.

The Company has not yet developed any share-based payment plan / scheme for its employees. Accordingly, no share-based payment arrangement has been recognized for the period.

13.1 The movement in treasury shares during the period / year is as follows:

	June 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Balance at beginning of the period / year	**-**	-
Shares repurchased during the period	**666,920**	-
Balance at the end of the period / year	**666,920**	-

14. DIVIDEND

For the period ended June 30, 2026
On March 1, 2026, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 15, 2025, resolved to distribute cash dividend amounted to ⃁ 6,160,000 (⃁ 0.08 per share) for the second half of the year 2025. The declared dividend during the period ended June 30, 2026 was paid on May 19, 2026.

For the period ended June 30, 2025
On March 17, 2025, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 24, 2024, resolved to distribute cash dividend amounted to ⃁ 3,850,000 (⃁ 0.05 per share) for the year 2024 and it was paid on May 25, 2025.

15. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the profit for the period attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period. As a result of treasury shares (note 13), the outstanding weighted average number of ordinary shares post the treasury shares have been used for calculation of basic and diluted earnings per ordinary share.

(All amounts expressed in Saudi Riyals "⃁" unless otherwise mentioned)

15. EARNINGS PER SHARE (CONTINUED)

Earnings per share are represented as follows:

	For the three-month ended		For the six-month ended	
	June 30, 2026 (Un-audited)	June 30, 2025 (Un-audited)	**June 30, 2026 (Un-audited)**	June 30, 2025 (Un-audited)
Net profit for the period	**3,496,943**	831,556	**6,535,818**	8,276,899
Weighted average number of ordinary shares	**76,930,541**	77,000,000	**76,963,346**	77,000,000
Basic and diluted earnings per share	**0.05**	0.01	**0.08**	0.11

16. MEASUREMENT OF FAIR VALUE

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, on the assumption that market participants act in their economic best interest.
All assets and liabilities that are measured at fair value or whose fair value is disclosed in the interim condensed financial statements are classified according to the scope of the fair value hierarchy shown below:

- Level 1: Quoted (unadjusted) prices quoted in active markets for assets or liabilities that are identical to those being measured.
- Level 2: The inputs that can be observed or monitored for the asset or liability, directly or indirectly, other than the published prices included within the first level.
- Level 3: Inputs that cannot be observed for the asset or liability

The Company believes that the carrying values of its financial assets and financial liabilities as of June 30, 2026, and June 30, 2025 approximate their fair values. The investments measured at fair value through profit or loss represent investments in equity securities traded in active market and are classified at Level 1 of the fair value hierarchy.

17. CONTINGENCIES AND COMMITMENTS

As at June 30, 2026, the Company has letters of guarantees amounted to ⃁ 2,133,559 (December 31, 2025: ⃁ Nil) issued from bank in the Kingdom of Saudi Arabia.

18. GEOPOLITICAL DEVELOPMENTS

The Company continues to monitor the regional geopolitical developments and their potential impact on Kingdom of Saudi Arabia given that all of the Company's operations are conducted within the Kingdom of Saudi Arabia. These developments have not had a material impact on Company's interim condensed financial statements for the period ended June 30, 2026. As the situation is evolving, management will continue to monitor developments and assess any potential impact as part of its normal reporting and risk management processes for future periods, as well.

19. SUBSEQUENT EVENT

On August 06, 2026, the Board of Directors resolved to recommend to the Extra Ordinary General Assembly, an increase in the Company's share capital by granting bonus shares to the shareholders at a ratio of one bonus share for every four shares held. The proposed capital increase will be made by capitalizing an amount of ⃁ 19.25 million from the retained earnings. The said issuance of the bonus shares is subject to obtaining the necessary regulatory approvals and the approval of the Extraordinary General Assembly.

20. APPROVAL OF THE INTERIM CONDENSED FINANCIAL STATEMENTS

These interim condensed financial statements were approved by the Board of Directors of the Company on August 06, 2026.